(Reuters) – Supernus Pharmaceuticals said on Tuesday its depression treatment trial failed to meet the main goal of reduction in depressive symptoms, sending its shares down 22% aftermarket.
The company said the drug, SPN-820, did not show a statistically significant change compared to placebo when tested in 250 patients with treatment-resistant depression during a mid-stage trial.
The patients were tested with the Montgomery-Asberg Depression Rating Scale, which measures severity of various symptoms of depression such as sadness, inner tension, reduced sleep and inability to feel.
“We will continue to analyze these data and discuss the future of the program with our development partner, Navitor Pharmaceuticals,” said Supernus CEO Jack Khattar.
(Reporting by Christy Santhosh in Bengaluru; Editing by Alan Barona)
Comments